HSHavva Sezer

Havva Sezer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Havva Sezer has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Frequency and Characteristics of Antibody Negative Chronic Thyroiditis: An Experience from a Tertiary Center

    by Havva Sezer, Hande Bulut Canbaz

    Objective: Limited literature is relevant to antibody-negative chronic thyroiditis (AN-CT). The aim was to investigate the frequency and characteristics of AN-CT and explore the presence of other autoim mune and autoinflammatory diseases in patients with AN-CT. Methods: Consecutive participants in the follow-up above 18 years old diagnosed with hypothyroid ism caused by chronic thyroiditis (CT) between December 2016 and March 2024 were included in the study. A total of 767 euthyroid patients with CT under levothyroxine (LT4) treatment were analyzed retrospectively. The patient group was divided into 2 subgroups: antibody-negative and antibody positive. Characteristics and comorbid conditions were compared between the 2 groups. Results: There were 582 patients (75.9%) with classic Hashimoto’s thyroiditis (antibody-positive) and 185 patients (24.1%) with AN-CT in the study group. The female/male ratio was similar in the 2 groups (P = .730). The median body mass index was comparable between the 2 groups (P = .486). Median age (P = .003) and thyroid nodule frequency (P = .011) were significantly higher in the AN-CT group. The duration of hypothyroidism was shorter (P = .022), and the daily LT4 dose to achieve euthyroidism was lower (P < .001) in patients with AN-CT. The presence of other autoimmune and autoinflammatory diseases did not differ between the 2 groups. Conclusion: In this study group, AN-CT frequency was 24.1%. Older age, shorter duration of hypo thyroidism, higher thyroid nodule frequency, and lower daily LT4 dose to achieve euthyroidism were associated with AN-CT. However, patients with AN-CT had similar behavior relevant to other autoim mune and autoinflammatory disorders when compared with Hashimoto’s patients. Cite this article as: Sezer H, Canbaz HB. Frequency and characteristics of antibody negative chronic thyroiditis: an experience from a tertiary center. Endocrinol Res Pract. 2025;29(3):223-228.

  • Levotiroksin Tedavisi Alan Ötiroid Hashimoto Hastalarında Tiroid Dışı Kanserler: Tek Bir Tersiyer Merkezin Hastalarına Bakış

    by Havva Sezer

    Levotiroksin (LT4) tedavisi alan ötiroid Hashimoto hastalarında tiroid dışı kanser (TDK) sıklığını araştırmayı amaçladık. Ayrıca kanser gelişiminin demografik, klinik, biyokimyasal ve metabolik parametrelerle ilişkili olup olmadığını da belirledik. Aralık 2016 ile Aralık 2023 tarihleri arasında tek bir tersiyer merkezde Hashimoto tiroiditi (HT) kaynaklı hipotiroidi tanısı alan 18 yaş üzeri takipteki ardışık katılımcılar çalışmaya dahil edildi. Toplam 577 Hashimoto hastası retrospektif olarak analiz edildi. Çalışma popülasyonu TDK olup olmamasına göre iki alt gruba ayrıldı. Kanserli ve kansersiz hastalarda demografik, klinik, biyokimyasal ve metabolik parametreler karşılaştırıldı.Bulgular: Ortalama yaş 52,6±13,5 yıldı. Beş yüz yetmiş yedi hastanın %87,3'ü kadın, %12,7'si erkekti. HT’ne eşlik eden en sık iki komorbidite metabolik sendrom (%36,4) ve obezite (%31,2) idi. HT ile TDK’in birlikte görülme sıklığı %13,3 idi. En sık görülen iki kanser meme (%46,2) ve over (%8,7) oldu. Çok değişkenli analizde, ileri yaşın (OR 1,030, %95 CI 1,012-1,049, p=0,001), pozitif aile öyküsünün (OR 1,859, %95 CI 1,117-3,092, p=0,017) ve yüksek açlık kan şekerinin (OR) 1,022, %95 CI 1,007-1,037, p=0,005) artan kanser riski ile anlamlı pozitif korelasyona sahip olduğu bulunmuştur. Bu çalışma, LT4 tedavisi alan ötiroid Hashimoto hastalarında TDK sıklığının %13,3 olduğunu ortaya çıkardı. Meme kanseri, çalışma popülasyonunu etkileyen en yaygın kanserdi. İleri yaş, pozitif aile öyküsü ve yüksek açlık kan şekeri, kanser gelişimi için bağımsız risk faktörleri olarak tanımlandı.

  • Previous, simultaneous, or subsequent occurrence of malignant tumours in patients with primary hyperparathyroidism: a closer look at the single-tertiary-centre cases

    by Havva Sezer, Hande Bulut Canbaz, Serdar Tezalman, Tarık Terzioğlu, Eda Nur Çilingiroğlu, Bülent Çolakoğlu, Dilek Yazıcı, Oğuzhan Deyneli, Mehmet Onur Demirkol, Adnan Batman, et al.

    Introduction: Our aims were to explore the relationship between primary hyperparathyroidism (pHPT) and malignant tumour development, to determine the frequency and the time of occurrence of malignant tumours in patients with pHPT, and to evaluate the characteristics of pHPT in these patients. Material and methods: This retrospective cohort study included consecutive individuals who were diagnosed with pHPT aged 18 years or older in a university hospital during a 7-year period. A total of 198 patients with pHPT were reviewed retrospectively. Demographic, clinical, biochemical, radiologic findings, and histopathological diagnosis were collected from the electronic medical records of the hospital system. Results: The mean age of the study population was 58 ± 13 years and was predominantly female (female/male: 162/36). There were 42 (21.2%) patients with malignant tumours. Five (12%) out of 42 patients had metachronous double malignancies. The most common 2 concurrent malignancies were breast (36.1%) and thyroid (17.0%). Sixty-eight per cent of the malignant tumours occurred before the diagnosis of pHPT. A higher percentage (87.5%) of simultaneous tumours was seen in the thyroid gland. No statistically significant differences were observed between patients with and without malignant tumours in terms of demographic, clinical, biochemical, radiological, and histopathological features. The median follow-up duration was 24 months after parathyroid surgery. Conclusion: The results of this study revealed that pHPT was associated with various tumour types. The frequency of malignant tumours was 21.2%. Breast and thyroid cancers were the most common 2 cancers coexisting with pHPT. A large percentage of malignant tumours occurred before the diagnosis of pHPT. A higher percentage of simultaneous tumours was seen in the thyroid gland. pHPT patients with and without malignant tumours seemed to have similar characteristics. Introduction: Our aims were to explore the relationship between primary hyperparathyroidism (pHPT) and malignant tumour development, to determine the frequency and the time of occurrence of malignant tumours in patients with pHPT, and to evaluate the characteristics of pHPT in these patients. Material and methods: This retrospective cohort study included consecutive individuals who were diagnosed with pHPT aged 18 years or older in a university hospital during a 7-year period. A total of 198 patients with pHPT were reviewed retrospectively. Demographic, clinical, biochemical, radiologic findings, and histopathological diagnosis were collected from the electronic medical records of the hospital system. Results: The mean age of the study population was 58 ± 13 years and was predominantly female (female/male: 162/36). There were 42 (21.2%) patients with malignant tumours. Five (12%) out of 42 patients had metachronous double malignancies. The most common 2 concurrent malignancies were breast (36.1%) and thyroid (17.0%). Sixty-eight per cent of the malignant tumours occurred before the diagnosis of pHPT. A higher percentage (87.5%) of simultaneous tumours was seen in the thyroid gland. No statistically significant differences were observed between patients with and without malignant tumours in terms of demographic, clinical, biochemical, radiological, and histopathological features. The median follow-up duration was 24 months after parathyroid surgery. Conclusion: The results of this study revealed that pHPT was associated with various tumour types. The frequency of malignant tumours was 21.2%. Breast and thyroid cancers were the most common 2 cancers coexisting with pHPT. A large percentage of malignant tumours occurred before the diagnosis of pHPT. A higher percentage of simultaneous tumours was seen in the thyroid gland. pHPT patients with and without malignant tumours seemed to have similar characteristics.

  • Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer

    by Havva Sezer, Dilek Yazıcı, Tarık Terzioğlu, Serdar Tezelman, Hande Bulut Canbaz, Aslıhan Yerlikaya, Mehmet Onur Demirkol, Yersu Kapran, Bülent Çolakoğlu, Eda Nur Çilingiroğlu, et al.

    Aim: The aims of the study are to evaluate the predictive value of early post-operative stimulated thyroglobulin (sTg) analysis on the recurrence risk, and to define a cut-off value that is related to recurrence risk in low to intermediate risk papillary thyroid cancer (PTC). Methods: This retrospective cohort study included individuals who were diagnosed with PTC aged 18 years or older and had been operated by experienced surgeons of a tertiary university hospital between the years 2011 and 2021. The American Thyroid Association thyroid cancer guidelines version 2015 was used as the risk stratification system. Early sTg measurement obtained at 3-4 weeks after surgery when TSH >30 µIU/mL. Data was collected from the hospital database. A total of 328 patients who had post-operative early sTg values with negative anti-Tg antibodies were included. Results: The median age was 44 years. Of the 328 patients, 223 (68%) were women. The median tumor diameter was 11 mm. One hundred ninety-one patients (58.2%) had low risk and 137 (41.8%) had intermediate risk for recurrent disease. Of the 328 patients, 4.0% had recurrent disease. In multivariate Cox regression, post-operative early sTg value [OR: 1.070 (1.038-1.116), P = .000], and the pre-operative malign cytology [OR: 1.483 (1.080-2.245), P = .042] were independent risk factors for recurrence. On the ROC curve analysis, the cut-off value of early sTg was 4.1 ng/mL for those with recurrent disease. Conclusion: This study demonstrated that early sTg could predict recurrent disease in patients with low to intermediate risk PTC. A cut-off of 4.1 ng/mL was identified with a high negative predictive value.


  • Open Access

    Subacute THYROiditis Related to SARS-CoV-2 VAccine and Covid-19 (THYROVAC Study): A Multicenter Nationwide Study

    by Adnan Batman, Dilek Yazıcı, Oğuz Dikbaş, Kemal Ağbaht, Emre Sedar Saygılı, İbRahim Demirci, Nurbanu Bursa, Görkem Ayas, Cüneyd Anıl, Mustafa Cesur, et al.

    Context: The aims of the study are to compare characteristics of subacute thyroiditis (SAT) related to different etiologies, and to identify predictors of recurrence of SAT and incident hypothyroidism. Methods: This nationwide, multicenter, retrospective cohort study included 53 endocrinology centers in Turkey. The study participants were divided into either COVID-19–related SAT (Cov-SAT), SARS-CoV-2 vaccine–related SAT (Vac-SAT), or control SAT (Cont-SAT) groups. Results: Of the 811 patients, 258 (31.8%) were included in the Vac-SAT group, 98 (12.1%) in the Cov-SAT group, and 455 (56.1%) in the Cont-SAT group. No difference was found between the groups with regard to laboratory and imaging findings. SAT etiology was not an independent predictor of recurrence or hypothyroidism. In the entire cohort, steroid therapy requirement and younger age were statistically significant predictors for SAT recurrence. C-reactive protein measured during SAT onset, female sex, absence of antithyroid peroxidase (TPO) positivity, and absence of steroid therapy were statistically significant predictors of incident (early) hypothyroidism, irrespective of SAT etiology. On the other hand, probable predictors of established hypothyroidism differed from that of incident hypothyroidism. Conclusion: Since there is no difference in terms of follow-up parameters and outcomes, COVID-19– and SARS-CoV-2 vaccine–related SAT can be treated and followed up like classic SATs. Recurrence was determined by younger age and steroid therapy requirement. Steroid therapy independently predicts incident hypothyroidism that may sometimes be transient in overall SAT and is also associated with a lower risk of established hypothyroidism.


  • Open Access

    Is obesity paradox valid for critically-ill COVID-19 patients with respiratory failure?

    by Havva Sezer, Hande Bulut Canbaz, Fatma Yurdakul, Bogac Ozserezli, Dilek Yazici

    Body mass index,acute respiratory distress syndrome,COVID-19,obesity paradox,mortality


  • Open Access

    The Frequency of Acceptance of Oral Glucose Tolerance Test in Turkish Pregnant Women: a single tertiary center results

    by Havva Sezer, Dilek Yazici, Hande Bulut Canbaz, Bahar Bekdemir, Mehmet Gokhan Gonenli, Aslihan Yerlikaya, Baris Ata, Emine Ayca Nalbantoglu

    OBJECTIVE: It is thought that there is not enough data about the frequency of acceptance of oral glucose tolerance test (OGTT) in Turkish pregnant women. The aim of this study was to investigate the frequency of acceptance of OGTT among participants in our single tertiary center. METHODS: The data of non-diabetic 344 pregnant women seen at the Obstetrics Clinic of our hospital between September 2016 and September 2017 were obtained from the hospital records. Women who did not have regular follow-up during pregnancy were excluded. One of the two or one-step approaches was used in the diagnosis of gestational diabetes mellitus (GDM) depending on the choice of the physician following the patient. RESULTS: There were 223 subjects eligible for the study. One hundred seventy-seven pregnant women (79.4%) accepted to do OGTT. We determined that 46 women (20.6%) did not complete at least one OGTT, of whom 74% (n=34) never completed the recommended screening test in this cohort. The overall frequency of GDM was approximately 15.2% (n=34). OGTT acceptability was higher among pregnant women with university graduates (p=0.02). Adverse pregnancy outcomes were similar between the accepted and rejected groups. Among the reasons for OGTT rejection, the media had a significant influence (n=35). CONCLUSION: Our results show that a significant percentage of patients refused to do OGTT. Therefore the actual frequency of pregnant women with GDM could not be determined. One way to increase compliance may be recommending only the one-step test for pregnant women in countries with a high rejection rate of OGTT.


  • Open Access

    Concomittant occurence of well-differentiated thyroid carcinoma metastasis and chronic lymphocytic leukemia in the same lymph node along with internal jugular vein thrombus

    by Havva Sezer, Dilek Yazıcı, Serdar Tezelman, Mehmet O. Demirkol, Ömer F. Ünal, Şükrü Dilege, Orhun Ç Taşkın, Önder Peker, Yersu Kapran, Bülent Çolakoğlu, et al.

    Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common adult leukemia. The coexistence of CLL and papillary thyroid carcinoma (PTC) is extremely rare. PTC sometimes shows microscopic vascular invasion but rarely cause a tumor thrombus in the internal jugular vein (IJV). It is also rare to find both differentiated and poorly differentiated types of thyroid cancer in the same metastatic location. We report a case of 63-year-old Turkish man with history of CLL who had CLL/SLL involvement and PTC metastasis in the same lymph node. Additionally, there was macroscopic metastasis to the IJV with poorly differentiated areas in the removed tumor thrombus. Patient was treated with total thyroidectomy, left radical neck dissection, resection of the left IJV segment that contained the tumor thrombus and radioactive iodine (RAI) therapy. Furthermore, metastatic lesions were found in the brain, lung and bone. Radiotherapy and chemotherapy were performed. However, our patient died approximately 12 months after thyroidectomy. To our knowledge, our present report is the first description with its current features.


  • The relationship between glycemic variability and blood pressure variability in normoglycemic normotensive individuals

    by Havva Sezer, Dilek Yazici, Sidar Copur, Tuncay Dagel, Oguzhan Deyneli, Mehmet Kanbay

    Background and aim: Glycemic fluctuations around a mean glucose level, referred as glycemic variability and blood pressure variability (BPV) are considered as independent risk factors for cardiovascular diseases, all-cause mortality, and cardiovascular disease-mortality. With this background in mind, we aimed to investigate the association between glycemic variability and BPV and their association in normoglycemic and normotensive individuals. Materials and method: Twenty-seven normotensive normoglycemic individuals were recruited. Twenty-four hour Holter devices were utilized to measure ambulatory blood pressure (BP) while continuous glucose monitoring (CGM) devices were applied to measure glycemic variability simultaneously to the subjects. These devices were kept on for 48 h. For BP recordings, daytime, nighttime, and 24-h BP determinations, their mean and SD were calculated. From CGM measurements, mean blood glucose (MBG), SD of blood glucose, the mean amplitude of glycemic excursions (MAGE), the mean of daily differences (MODD), coefficient of variation (correction of variability for the MBG), and daytime and nighttime blood glucose were determined. Results: The mean age of the subjects was 23.8 ± 2.7 years and 66% were women (18/27). In the correlation analysis between glycemic variability parameters and BPV parameters, SD of 24-h SBP was correlated with the SD of MBG (r = 0.52, P = 0.006), MAGE (r = 0.49, P = 0.009), and MODD (r = 0.46, P = 0.015). SD of daytime SBP was correlated with, MAGE (r = 0.42, P = 0.03) and MODD (r = 0.43, P = 0.02). Conclusion: We report correlation between glycemic variability and BPV variables in normoglycemic and normotensive healthy individuals.


  • Open Access

    Empagliflozin-induced ketoacidosis in a patient presenting with new-onset type 2 diabetes mellitus due to indolent pancreatic cancer

    by Havva Sezer, Dilek Yazıcı, Oğuzhan Deyneli, Çişel Meriçöz, Ayla Esin, Emrah Alper

    Not required for Clinical Vignette. Not required for Clinical Vignette.